About Volition
Volition is a company based in Gembloux (Belgium) founded in 1995. It operates as a HealthTech and Professional Services. The company has 85 employees as of December 31, 2024. Volition has completed 1 acquisition, including Octamer. Volition offers products and services including Nu.Q® NETs, Nu.Q® Vet Cancer Test, Nu.Q® Discover, and Nu.Q® Cancer. Volition operates in a competitive market with competitors including Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Gembloux, Belgium
- Employees 85 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Volitionrx Limited
-
Annual Revenue
$1.23 M (USD)59.1as on Dec 31, 2024
-
Net Profit
-$26.97 M (USD)23.65as on Dec 31, 2024
-
EBITDA
-$25.72 M (USD)25.61as on Dec 31, 2024
-
Latest Funding Round
$2.32 M (USD), Post-IPO
Mar 31, 2026
-
Investors
Belgium
& 2 more
-
Employee Count
85
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Volition
Volition is a publicly listed company on the AMEX with ticker symbol VNRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Volition
Volition offers a comprehensive portfolio of products and services, including Nu.Q® NETs, Nu.Q® Vet Cancer Test, Nu.Q® Discover, and Nu.Q® Cancer.
A CE-marked test for detecting NETosis in patients.
Blood test for detecting cancer in dogs affordably.
Assays for epigenetic profiling in drug development studies.
Blood-based assays for cancer detection and beyond.
People of Volition
Unlock access to complete
Unlock access to complete
Software Development Team
12 people
Leadership Team
11 people
Product Management Team
5 people
Scientist Team
3 people
Sales and Marketing
3 people
Human Resources and Administration
2 people
Legal and Compliance
2 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Volition
Investors in Volition
Volition has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Belgium, Wallonie Entreprendre and Namur Invest.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Official Belgian government information and services are provided online.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Volition
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Volition
Volition has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Octamer.
Investment portfolio details for Volition
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of screening substrates for epigenetics research
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Volition
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Volition
Detailed financials for Volition
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Volition Comparisons
Peer comparison for Volition
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Volition
Volition operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Color, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
Detailed competitors of Volition
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Volition
Complete news archive for Volition
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Volition
Volition was founded in 1995 and raised its 1st funding round 17 years after it was founded.
Volition is headquartered in Gembloux, Belgium. It is registered at Gembloux, Namur, Belgium.
Cameron Reynolds is the current CEO of Volition.
As of Dec 31, 2024, the latest employee count at Volition is 85.
Annual revenue of Volition is $1.23M as on Dec 31, 2024.
Volition is engaged in advancing the science of epigenetics to revolutionize the diagnosis and monitoring of life-altering diseases such as cancer and sepsis. The company develops blood-based diagnostic tests using its proprietary Nu.Q technology, which detects characteristic epigenetic changes in nucleosomes from the earliest disease stages. Solutions are offered for human health, including NETosis detection, and veterinary applications like cancer screening in dogs. Additionally, research assays under the Nu.Q Discover program support drug development and clinical studies. Operating across multiple sectors, Volition collaborates globally with academic institutions and pharmaceutical companies from its offices in the USA, UK, Belgium, and Singapore.
Volition's top competitors include Guardant Health, GRAIL and BillionToOne.
Volition offers Nu.Q® NETs, Nu.Q® Vet Cancer Test, Nu.Q® Discover, and Nu.Q® Cancer.
Yes, Volition is publicly traded on AMEX under the ticker symbol VNRX.
Volition has made 1 acquisition, including Octamer.
Volition has 3 investors. Key investors include Belgium, Wallonie Entreprendre, and Namur Invest.
The ticker symbol of Volition is VNRX on AMEX.